NAPROXEN SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H13O3.Na
Molecular Weight	252.241
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C([O-])=O

InChI

InChIKey=CDBRNDSHEYLDJV-FVGYRXGTSA-M

InChI=1S/C14H14O3.Na/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;/h3-9H,1-2H3,(H,15,16);/q;+1/p-1/t9-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C14H13O3
Molecular Weight	229.2512
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017581s112,018164s062,020067s019lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68009288

Naproxen (naproxen sodium, NAPROSYN®) is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). It is an anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. The mechanism of action of the naproxen (naproxen sodium, NAPROSYN®), like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-1 127 Target ID: CHEMBL221 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017581s112,018164s062,020067s019lbl.pdf	Inhibitor 8297		0.11 µM [IC50]
Cyclooxygenase-2 196 Target ID: CHEMBL230 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017581s112,018164s062,020067s019lbl.pdf	Inhibitor 8297		0.19 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Rheumatoid arthritis 316 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017581s112,018164s062,020067s019lbl.pdf	Primary	Approved 8429	NAPROSYN Approved Use NAPROSYN is indicated: For the relief of the signs and symptoms of rheumatoid arthritis. For the relief of the signs and symptoms of osteoarthritis. For the relief of the signs and symptoms of ankylosing spondylitis. For the relief of the signs and symptoms of juvenile arthritis. NAPROSYN is also indicated: For relief of the signs and symptoms of tendonitis. For relief of the signs and symptoms of bursitis. For relief of the signs and symptoms of acute gout. For the management of pain. For the management of primary dysmenorrhea. Launch Date 1976
Osteoarthritis 157 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017581s112,018164s062,020067s019lbl.pdf	Primary	Approved 8429	NAPROSYN Approved Use NAPROSYN is indicated: For the relief of the signs and symptoms of rheumatoid arthritis. For the relief of the signs and symptoms of osteoarthritis. For the relief of the signs and symptoms of ankylosing spondylitis. For the relief of the signs and symptoms of juvenile arthritis. NAPROSYN is also indicated: For relief of the signs and symptoms of tendonitis. For relief of the signs and symptoms of bursitis. For relief of the signs and symptoms of acute gout. For the management of pain. For the management of primary dysmenorrhea. Launch Date 1976
Ankylosing spondylitis 33 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017581s112,018164s062,020067s019lbl.pdf	Primary	Approved 8429	NAPROSYN Approved Use NAPROSYN is indicated: For the relief of the signs and symptoms of rheumatoid arthritis. For the relief of the signs and symptoms of osteoarthritis. For the relief of the signs and symptoms of ankylosing spondylitis. For the relief of the signs and symptoms of juvenile arthritis. NAPROSYN is also indicated: For relief of the signs and symptoms of tendonitis. For relief of the signs and symptoms of bursitis. For relief of the signs and symptoms of acute gout. For the management of pain. For the management of primary dysmenorrhea. Launch Date 1976
Tendonitis 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017581s112,018164s062,020067s019lbl.pdf	Primary	Approved 8429	NAPROSYN Approved Use NAPROSYN is indicated: For the relief of the signs and symptoms of rheumatoid arthritis. For the relief of the signs and symptoms of osteoarthritis. For the relief of the signs and symptoms of ankylosing spondylitis. For the relief of the signs and symptoms of juvenile arthritis. NAPROSYN is also indicated: For relief of the signs and symptoms of tendonitis. For relief of the signs and symptoms of bursitis. For relief of the signs and symptoms of acute gout. For the management of pain. For the management of primary dysmenorrhea. Launch Date 1976
Bursitis 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017581s112,018164s062,020067s019lbl.pdf	Primary	Approved 8429	NAPROSYN Approved Use NAPROSYN is indicated: For the relief of the signs and symptoms of rheumatoid arthritis. For the relief of the signs and symptoms of osteoarthritis. For the relief of the signs and symptoms of ankylosing spondylitis. For the relief of the signs and symptoms of juvenile arthritis. NAPROSYN is also indicated: For relief of the signs and symptoms of tendonitis. For relief of the signs and symptoms of bursitis. For relief of the signs and symptoms of acute gout. For the management of pain. For the management of primary dysmenorrhea. Launch Date 1976

C_max

Value	Dose	Co-administered	Analyte	Population
95 μg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020353s034lbl.pdf	500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NAPROXEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
94 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020353s034lbl.pdf	1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NAPROXEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1446 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020353s034lbl.pdf	500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NAPROXEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
1448 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020353s034lbl.pdf	1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NAPROXEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
15 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020353s034lbl.pdf	500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NAPROXEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020353s034lbl.pdf	500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NAPROXEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
12.5 g single, oral Overdose Dose: 12.5 g Route: oral Route: single Dose: 12.5 g Sources: https://pubmed.ncbi.nlm.nih.gov/2552870 Page: 1102/129	healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2552870 Page: 1102/129	Disc. AE: Abdominal pain, Nausea... AEs leading to discontinuation/dose reduction: Abdominal pain Nausea Dizziness Seizures Metabolic acidosis (severe) Sources: https://pubmed.ncbi.nlm.nih.gov/2552870 Page: 1102/129
4 g single, oral Highest studied dose Dose: 4 g Route: oral Route: single Dose: 4 g Sources: https://pubmed.ncbi.nlm.nih.gov/954349/ Page: p.272	healthy, 20 n = 4 Health Status: healthy Age Group: 20 Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/954349/ Page: p.272	Sources: https://pubmed.ncbi.nlm.nih.gov/954349/ Page: p.272
70.4 g single, oral Overdose Dose: 70.4 g Route: oral Route: single Dose: 70.4 g Co-administed with:: alcohol, p.o Sources: https://pubmed.ncbi.nlm.nih.gov/24756481 Page: p.103	healthy, 28 n = 1 Health Status: healthy Age Group: 28 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/24756481 Page: p.103	Disc. AE: Sinus tachycardia, Drowsiness... AEs leading to discontinuation/dose reduction: Sinus tachycardia Drowsiness Metabolic acidosis Seizures Sources: https://pubmed.ncbi.nlm.nih.gov/24756481 Page: p.103
26 g single, oral Overdose Dose: 26 g Route: oral Route: single Dose: 26 g Sources: https://pubmed.ncbi.nlm.nih.gov/31742906 Page: p.458	unhealthy, 58 n = 1 Health Status: unhealthy Condition: Depressive syndrome\|Anxiety Age Group: 58 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/31742906 Page: p.458	Disc. AE: Thrombopenia... AEs leading to discontinuation/dose reduction: Thrombopenia Sources: https://pubmed.ncbi.nlm.nih.gov/31742906 Page: p.458
550 mg 2 times / day multiple, oral Recommended Dose: 550 mg, 2 times / day Route: oral Route: multiple Dose: 550 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Pain\|Primary Dysmenorrhea\| Acute Tendonitis\| Acute Bursitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf Page: p.1	Disc. AE: Cardiac thrombosis, Myocardial infarction... AEs leading to discontinuation/dose reduction: Cardiac thrombosis (grade 3-5) Myocardial infarction (grade 3-5) Stroke (grade 3-5) Gastrointestinal disorder NOS (grade 3-5) Gastrointestinal bleeding (grade 3-5) Gastrointestinal ulcer (grade 3-5) Perforation stomach (grade 3-5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf Page: p.1

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	substrate 1037

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT4 146 OAT3 642 OAT1 599 OAT2 145	CYP1A2 1054 CYP2C8 693 UGT1A1 418 UGT1A3 422 UGT1A6 307 UGT1A7 236 UGT1A8 283 UGT1A9 380 UGT1A10 291 UGT2B7 389

Drug as perpetrator

Target	Modality	Activity
OAT3 644	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/12388633/	yes [IC50 4.67 uM]
OAT2 147	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/12388633/	yes [IC50 486 uM]
OAT1 603	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/12388633/	yes [IC50 5.67 uM]
OAT4 146	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/12388633/	yes [IC50 85.4 uM]

Drug as victim

Target	Modality	Activity
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9248768/	major
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9248768/	minor
CYP2C8 693	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9248768/	minor
UGT1A1 418	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884820/	yes
UGT1A10 291	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884820/	yes
UGT1A3 422	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884820/	yes
UGT1A6 307	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884820/	yes
UGT1A7 236	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884820/	yes
UGT1A8 283	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884820/	yes
UGT1A9 380	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884820/	yes
UGT2B7 389	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884820/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7476	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7476
ChemicalBook	CB8274937	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8274937
ChemicalBook	CB8422325	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8422325
MolPort	MolPort-000-145-960	https://www.molport.com/shop/molecule-link/MolPort-000-145-960
ZINC	ZINC000000105216	http://zinc15.docking.org/substances/ZINC000000105216
eMolecules	494695	https://www.emolecules.com/cgi-bin/more?vid=494695

PubMed

Title	Date	PubMed
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.	1999 Jul	10430112
Low-dose diclofenac, naproxen, and ibuprofen cohort study.	1999 Jul	10417034
Long-term followup of naproxen-induced pseudoporphyria in juvenile rheumatoid arthritis.	1999 Oct	10524703
Naproxen-induced leukocytoclastic vasculitis.	2000	10870665
[Aspirin-induced angioedema of the nape of the neck with naproxen cross-reaction: a case report].	2000 May	10896977
Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride.	2000 Sep	11304721
Differential regulation of interleukin-1 beta-induced cyclooxygenase-2 gene expression by nimesulide in human synovial fibroblasts.	2001	11296546
Nimesulide, a balanced drug for the treatment of osteoarthritis.	2001	11296545
Naproxen availability from variable-dose and weight sustained-release tablets.	2001	11291202
Naproxen particle design using porous starch.	2001 Apr	11411896
Naproxen-Eudragit microspheres: screening of process and formulation variables for the preparation of extended release tablets.	2001 Apr	11338673
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.	2001 Apr	11316141
Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts.	2001 Apr	11315999
Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.	2001 Apr	11315375
Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes.	2001 Apr	11300749
Risk of ulcer soars with combination of arthritis drugs.	2001 Apr	11290669
Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.	2001 Feb	11246553
Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry.	2001 Feb 23	11263577
[Drug-induced aphthae].	2001 Jan	11291642
Isolated tuberculous monoarthritis mimicking oligoarticular juvenile rheumatoid arthritis.	2001 Jan	11196526
Successful use of propranolol in migraine associated with electroconvulsive therapy.	2001 Jan	11168610
Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal anti-inflammatory drugs.	2001 Jan 19	11166741
[Liver damage and nonsteroidal anti-inflammatory drugs: case non-case study in the French Pharmacovigilance Database].	2001 Jan-Feb	11322018
A possible mechanism of naproxen-induced lipid peroxidation in rat liver microsomes.	2001 Jul	11484909
Determination of ibuprofen and naproxen in tablets.	2001 Jul	11377071
[Treatment of pain due to unwanted lactation with a homeopathic preparation given in the immediate post-partum period].	2001 Jun	11431615
Treatment of de Quervain's disease:role of conservative management.	2001 Jun	11386780
Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammatory drugs in vitro.	2001 Jun	11386772
[Nitric oxide and gastroduodenal damage caused by NSAIDs. Recent findings and clinical implications].	2001 Mar	11320858
Synthesis and cyclooxygenase inhibitory properties of novel (+) 2-(6-methoxy-2-naphthyl)propanoic acid (naproxene) derivatives.	2001 Mar	11315336
Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy.	2001 Mar	11298105
Interleukin-6 (IL-6) producing phaeochromocytoma: direct IL-6 suppression by non-steroidal anti-inflammatory drugs.	2001 Mar	11298095
Acute postoperative swelling after hand surgery: an exploratory, double-blind, randomised study with paracetamol, naproxen, and placebo.	2001 Mar	11291357
Anti-lymphoma effect of naproxen and indomethacin in a patient with relapsed diffuse large B-cell lymphoma.	2001 Mar	11279630
High-performance liquid chromatographic method development and validation for the simultaneous quantitation of naproxen sodium and pseudoephedrine hydrochloride impurities.	2001 Mar	11277256
Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis.	2001 Mar	11269574
Is rofecoxib safer than naproxen?	2001 Mar	11252204
Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn.	2001 Mar	11230592
Prostaglandin biosynthesis by fat body from true armyworms, Pseudaletia unipuncta.	2001 Mar 15	11222953
Simultaneous quantification of neutral and acidic pharmaceuticals and pesticides at the low-ng/l level in surface and waste water.	2001 Mar 16	11293584
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.	2001 Mar 29	11274623
[The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].	2001 May	11413920
Severe reversible renal failure due to naproxen-associated acute interstitial nephritis.	2001 May	11388597
Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care.	2001 May	11380750
The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-beta-cyclodextrin.	2001 May	11297903
Stereoselective synthesis of (S)-(+)-Naproxen catalyzed by carboxyl esterase in a multicompartment electrolyzer.	2001 May 28	11384761
Upper gastrointestinal toxicity of rofecoxib and naproxen.	2001 May 3	11336057
Upper gastrointestinal toxicity of rofecoxib and naproxen.	2001 May 3	11336056
Isotachophoretic determination of naproxen in the presence of its metabolite in human serum.	2001 May 4	11382293
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.	2001 May-Jun	11386636

Patents

Sample Use Guides

In Vivo Use Guide

Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis: 1 tablet of NAPROSYN® (250 mg or 375 mg or 500 mg) twice daily. Acute Gout: The recommended starting dose is 750 mg of NAPROSYN® followed by 250 mg every 8 hours until the attack has subsided.

Route of Administration: Oral

In Vitro Use Guide

There are data on the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen (Flu-AM1 and Nap-AM1, respectively) with respect to their properties towards fatty acid amide hydrolase (FAAH). Flu-AM1 and Nap-AM1 inhibited FAAH-catalysed hydrolysis of [(3)H]anandamide by rat brain homogenates with IC50 values of 0.44 and 0.74 uM. The corresponding values for flurbiprofen and naproxen were 29 and >100 uM, respectively.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:20:18 GMT 2023` Edited by `admin` on `Fri Dec 15 15:20:18 GMT 2023`
Record UNII	9TN87S3A3C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NAPROXEN SODIUM

Official Name

English

NAPROXEN SODIUM COMPONENT OF TREXIMET

Common Name

English

NAPRELAN

Brand Name

English

NAPROXEN SODIUM [ORANGE BOOK]

Common Name

English

NAPROXEN SODIUM [EP IMPURITY]

Common Name

English

2-NAPHTHALENEACETIC ACID, 6-METHOXY-.ALPHA.-METHYL-, SODIUM SALT, (S)-

Common Name

English

NAPROXEN SODIUM COMPONENT OF ALEVE-D

Common Name

English

NAPROXEN SODIUM [USAN]

Common Name

English

TREXIMET COMPONENT NAPROXEN SODIUM

Common Name

English

NAPROXEN SODIUM ANHYDROUS

Common Name

English

NAPROXEN SODIUM SALT

Common Name

English

BAY117031

Code

English

ANAPROX

Brand Name

English

NAPROXEN SODIUM SALT [MI]

Common Name

English

BAYH6689

Code

English

NAPROXEN SODIUM [USP MONOGRAPH]

Common Name

English

NAPROXEN SODIUM [USP IMPURITY]

Common Name

English

NAPROXEN SODIUM [EP MONOGRAPH]

Common Name

English

BAY-117031

Code

English

NAPROXEN SODIUM [VANDF]

Common Name

English

ALEVE

Brand Name

English

NAPROXEN SODIUM [MART.]

Common Name

English

Naproxen sodium [WHO-DD]

Common Name

English

ALEVE-D COMPONENT NAPROXEN SODIUM

Common Name

English

RS-3650

Code

English

NAPROXEN SODIUM [USP-RS]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1323